The Ashcroft firm was paid with stock options wort
Post# of 72440
That is NOT a contingency. That is the Ashcroft firm thinking that they are going to be exercising those options for 1.70 when the stock is worth much, much more.
I can't imagine a stronger vote of confidence in this stock, from people who have absolutely every bit of knowledge that the company has (because the company has disclosed EVERYTHING involving clinical trials etc. that is known, so that the Ashcroft firm can refute the Rosen/Mako lies).